GlassScriptPhysician profile
April Stubbs
NPI 1124693387
$571.31
in general payments reported to CMS, 2019-2025
15 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $194 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $171.63 | 2024-2025 | Farxiga, Breztri |
| Abbvie INC. | $84.65 | 2024-2025 | |
| Novo Nordisk INC | $63.25 | 2025 | Ozempic |
| Exact Sciences Corporation | $36.20 | 2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $28.44 | 2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $25.46 | 2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $23.16 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $19.76 | 2025 | Strensiq |
| Tms Neurohealth Centers INC. | $19.28 | 2025 | Tms Neurohealth Centers INC. |
| Merck Sharp & Dohme LLC | $18.88 | 2025 | Capvaxive, Gardasil 9 |
| Dynavax Technologies Corporation | $16.91 | 2025 | Heplisav-B |
| Amgen INC. | $16.69 | 2025 | Repatha, Otezla |
| Shield Therapeutics INC | $16.51 | 2025 | |
| Organon LLC | $15.88 | 2025 | Nexplanon |
| Stryker Corporation | $14.61 | 2025 | Clottriever Bold Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Stubbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.